Moshe Arkin Updates 56.6% Stake in Sol-Gel

Sol-Gel Technologies’ major shareholder Moshe Arkin filed Amendment No. 7 to Schedule 13D to update his ownership percentages after the company’s underwritten offering closed on March 25, 2026.

Rhea-AI Filing Summary

Sol-Gel Technologies’ major shareholder Moshe Arkin filed Amendment No. 7 to Schedule 13D to update his ownership percentages after the company’s underwritten offering closed on March 25, 2026.

As of that date, Arkin Dermatology owned 1,806,856 Ordinary Shares, representing about 52.44% of Sol-Gel’s outstanding Ordinary Shares. Moshe Arkin directly owned 143,257 Ordinary Shares, or about 4.41% of the company. Through his control of Arkin Dermatology, he may be deemed to beneficially own a total of 1,950,112 Ordinary Shares, representing approximately 56.60% of Sol-Gel’s Ordinary Shares, based on 3,245,270 shares outstanding on March 25, 2026.

Key Figures

Arkin Dermatology holdings: 1,806,856 Ordinary Shares Moshe Arkin direct holdings: 143,257 Ordinary Shares Total beneficial ownership (Arkin): 1,950,112 Ordinary Shares +3 more

6 metrics

Arkin Dermatology holdings 1,806,856 Ordinary Shares Directly owned; 52.44% of Sol-Gel outstanding as of March 25, 2026

Moshe Arkin direct holdings 143,257 Ordinary Shares Directly owned; 4.41% of Sol-Gel outstanding as of March 25, 2026

Total beneficial ownership (Arkin) 1,950,112 Ordinary Shares Combined direct and indirect; 56.60% of Sol-Gel outstanding as of March 25, 2026

Shares outstanding 3,245,270 Ordinary Shares Sol-Gel Ordinary Shares outstanding on March 25, 2026, per 424(b)(3) prospectus

Amendment number Amendment No. 7 Amendment to Schedule 13D for Sol-Gel Technologies Ltd

Underwritten offering closing date March 25, 2026 Ownership percentages updated following this offering’s closing

Key Terms

beneficial owner, shared power to vote, sole power to dispose, Schedule 13D, +1 more

5 terms

beneficial owner financial

"Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared power to vote financial

"Arkin Dermatology has the shared power to vote, or direct the voting of, the Ordinary Shares"

sole power to dispose financial

"Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, these Ordinary Shares"

Schedule 13D regulatory

"This amendment to is being filed solely to update the percentage holdings of the Reporting Persons"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

underwritten offering financial

"following the closing of the Issuer's underwritten offering that closed on March 25, 2026"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Schedule 13D/A reveal about Sol-Gel (SLGL) ownership?

The amendment shows that Moshe Arkin may be deemed to beneficially own 1,950,112 Sol-Gel Ordinary Shares, representing about 56.60% of shares outstanding. This reflects updated percentages following Sol-Gel’s underwritten offering that closed on March 25, 2026, without reporting new share purchases.

How many Sol-Gel (SLGL) shares does Arkin Dermatology hold after the offering?

Arkin Dermatology directly owns 1,806,856 Sol-Gel Ordinary Shares, representing approximately 52.44% of the company’s outstanding Ordinary Shares as of March 25, 2026. It holds shared voting and dispositive power over these shares, and its ownership percentage was recalculated after the company’s underwritten offering.

What is Moshe Arkin’s direct shareholding in Sol-Gel (SLGL)?

Moshe Arkin directly owns 143,257 Sol-Gel Ordinary Shares, equal to about 4.41% of the company’s outstanding Ordinary Shares as of March 25, 2026. He has sole voting and dispositive power over these directly held shares, separate from his indirect interest through Arkin Dermatology.

How is the 56.60% beneficial ownership for Moshe Arkin in Sol-Gel (SLGL) calculated?

The 56.60% figure combines Moshe Arkin’s direct holding of 143,257 Ordinary Shares with 1,806,856 Ordinary Shares held by Arkin Dermatology, which he controls as sole shareholder and director. Together, these total 1,950,112 shares out of 3,245,270 Sol-Gel Ordinary Shares outstanding on March 25, 2026.

Did the reporting persons trade Sol-Gel (SLGL) shares in the 60 days before this amendment?

The amendment states that, except as described in the filing, to the best knowledge of the reporting persons they have not engaged in any transactions in Sol-Gel Ordinary Shares during the past 60 days. The primary purpose of the amendment is to update ownership percentages after the underwritten offering.

On what share count are Sol-Gel (SLGL) ownership percentages based in this 13D/A?

All ownership percentages in the amendment are based on 3,245,270 Sol-Gel Ordinary Shares outstanding as of March 25, 2026. This outstanding share figure comes from Sol-Gel’s 424(b)(3) prospectus filed with the SEC on March 24, 2026, and is used consistently for the reported percentage calculations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 12:37 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

Sol-Gel Technologies Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 1.0 per share

(Title of Class of Securities)

M8694L137

(CUSIP Number)

Perry Wildes, Adv.
One Azrieli Center,
Tel Aviv, L3, 6701101
972-3-607-4444

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/25/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): M8694L137

1

Name of reporting person

Moshe Arkin

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 143,257.00
8	Shared Voting Power 1,806,856.00
9	Sole Dispositive Power 143,257.00
10	Shared Dispositive Power 1,806,856.00

11

Aggregate amount beneficially owned by each reporting person

1,950,113.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

56.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): M8694L137

1

Name of reporting person

M. Arkin Dermatology Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power
8	Shared Voting Power 1,806,856.00
9	Sole Dispositive Power
10	Shared Dispositive Power 1,806,856.00

11

Aggregate amount beneficially owned by each reporting person

1,806,856.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

52.44 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the Securities and Exchange Commission ("SEC") on March 24, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value NIS 1.0 per share
(b)	Name of Issuer: Sol-Gel Technologies Ltd
(c)	Address of Issuer's Principal Executive Offices: 7 Golda Meir St., Weizmann Science Park, Ness Tziona, ISRAEL , 7403648.
Item 3.	Source and Amount of Funds or Other Consideration
	This amendment to Schedule 13D is being filed solely to update the percentage holdings of the Reporting Persons following the closing of the Issuer's underwritten offering that closed on March 25, 2026.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 of Schedule 13D is hereby amended and restated as follows: (a) and (b) As of March 25, 2026, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares. Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. As of March 25, 2026, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 143,257 Ordinary Shares, which represented beneficial ownership of approximately 4.41% of the Company's outstanding Ordinary Shares. Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 1,806,856 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares. Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. The total Ordinary Shares beneficially owned by Mr. Arkin as of March 25, 2026, is 1,950,112, which represented beneficial ownership of 56.60% of the Company's outstanding Ordinary Shares.
(c)	Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares.
(d)	No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5. Percentages set forth in this amended Schedule 13D were calculated based on 3,245,270 Ordinary Shares outstanding on March 25, 2026 as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Moshe Arkin

Signature:	/s/ Moshe Arkin
Name/Title:	Moshe Arkin
Date:	04/13/2026

M. Arkin Dermatology Ltd.

Signature:	/s/ Moshe Arkin
Name/Title:	Moshe Arkin, Director
Date:	04/13/2026